Covered recipient · General Payments record
STEVEN E CATLETT
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$7,485.33
- Reported across 276 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $424.85 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $175.04 | 7 |
| Acerta Pharma LLC | $116.75 | 1 |
| GlaxoSmithKline, LLC. | $53.10 | 3 |
| Novo Nordisk AS | $46.61 | 3 |
| ABBVIE INC. | $19.97 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $13.38 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.97 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103429526 | CMS |
| Amgen Inc. | $9.63 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522781 | CMS |
| Amgen Inc. | $7.12 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522783 | CMS |
| Amgen Inc. | $121.84 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115485598 | CMS |
| Amgen Inc. | $8.71 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522785 | CMS |
| Amgen Inc. | $7.79 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115485589 | CMS |
| Amgen Inc. | $9.08 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522787 | CMS |
| Amgen Inc. | $10.87 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117522789 | CMS |
| AstraZeneca Pharmaceuticals LP | $116.75 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105609195 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $13.38 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086216621 | CMS |
| GlaxoSmithKline, LLC. | $13.37 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116577692 | CMS |
| GlaxoSmithKline, LLC. | $14.41 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116516430 | CMS |
| GlaxoSmithKline, LLC. | $25.32 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116336651 | CMS |
| Novo Nordisk Inc | $15.89 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097454557 | CMS |
| Novo Nordisk Inc | $13.78 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096930878 | CMS |
| Novo Nordisk Inc | $16.94 | 11/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096580307 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.